2nd Annual Hemophilia Drug Development Summit
Evvnt Promotion / evvnt
Archiv
20.08.2019 - 22.08.2019 Wyndham Boston Beacon Hill, 5 Blossom Street, 02114 Boston, USA
Time: 8:00 am - 5:00 pm
Kongressthemen
Given the excitement and anticipation of increasingly more promising prophylactic treatments and gene therapies, the 2nd Annual Hemophilia Drug Development Summit, once again unites leading pharma, biotech and academic KOLs working to translate and clinically develop longer acting and more efficacious therapies to overcome significant unmet medical need and hemophilia and other bleeding disorders.
Given the excitement and anticipation of increasingly more promising prophylactic treatments and gene therapies, the 2nd Annual Hemophilia Drug Development Summit, once again unites leading pharma, biotech and academic KOLs working to translate and clinically develop longer acting and more efficacious therapies to overcome significant unmet medical need and hemophilia and other bleeding disorders.
Kongressorganizer (PCO)
Hanson Wade
Hanson Wade
Anmerkungen
Brochure: https://go.evvnt.com/411348-2?pid=4832
Speakers: Howard Levy, Chief Medical Officer, Catalyst Biosciences, H. Trent Spencer,President, Expression Therapeutics
Brochure: https://go.evvnt.com/411348-2?pid=4832
Speakers: Howard Levy, Chief Medical Officer, Catalyst Biosciences, H. Trent Spencer,President, Expression Therapeutics
Anfragen und Anmeldung:
https://go.evvnt.com/411348-0?pid=4832
Herr Ilektra Stouka
Gesundheitsversorgung, Public Health
Sprache
Englisch
Englisch
Kongressgebühr
USD 3.697,00
(USD 1499.0 - USD 3697.0)
USD 3.697,00
(USD 1499.0 - USD 3697.0)
Veranstalter Kontakt
83 Great Titchfield Street
W1W 6RH London
Großbritannien
83 Great Titchfield Street
W1W 6RH London
Großbritannien
"GOING INTERNATIONAL fördert den Zugang zu Aus-, Fort- und Weiterbildung, unabhängig von sozialen, geographischen und nationalen Grenzen."
